Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfametrole is a sulfonamide antibiotic used primarily in combination with trimethoprim for the treatment of various bacterial infections. It belongs to the class of sulfonamides and acts as an antibacterial agent by inhibiting folic acid synthesis in bacteria. Sulfametrole is typically administered orally or intravenously and is available in some countries as a fixed-dose combination with trimethoprim. Its mechanism of action involves competitive inhibition of dihydropteroate synthase, an enzyme essential for bacterial folate synthesis, thereby blocking DNA and RNA production required for bacterial growth[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfametrole.